Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» #ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
Submitted by
admin
on December 10, 2017 - 11:10am
Source:
Endpoints
News Tags:
ASH17
Novartis
Kymriah
DLBCL
CAR-T
diffuse large B-cell lymphoma
Headline:
#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
Do Not Allow Advertisers to Use My Personal information
